Pacific Biosciences (PACB)

• Market cap: $422M
• 1 day: -6.10%
• 5 days: 7.69%
• 1 month: -9.41%
• 3 months: -12.99%
• 6 months: -0.65%
• Year to date: -14.44%
• 1 year: -69.69%
• 5 years: -63.25%
• 10 years: -77.58%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Employees: 796

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

64% more call options, than puts

Call options by funds: $6.83M | Put options by funds: $4.17M

21% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 63

20% more capital invested

Capital invested by funds: $396M [Q3] → $477M (+$81M) [Q4]

12% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 33

9.44% more ownership

Funds ownership: 85.34% [Q3] → 94.78% (+9.44%) [Q4]

1% less funds holding

Funds holding: 226 [Q3] → 223 (-3) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 3% downside
• Avg. target: $2 30% upside
• High target: $2.50 62% upside

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

Piper Sandler David Westenberg 51% 1-year accuracy 21 / 41 met price target	30% upside $2	Neutral Reiterated	20 Feb 2025
Goldman Sachs Matthew Sykes 56% 1-year accuracy 22 / 39 met price target	3% downside $1.50	Neutral Maintained	18 Feb 2025
Stephens & Co. Mason Carrico 40% 1-year accuracy 8 / 20 met price target	62% upside $2.50	Overweight Reiterated	18 Feb 2025